SRGN and breast cancer: Future studies should therefore investigate the molecular mechanisms behind this potential crosstalk, via serglycin, between the breast cancer cells and the infiltrating immune cells and if expression of serglycin by the immune cells can induce EMT in the breast cancer cells.